Phone: +385 1 8886300

Email: fidelta@glpg.com

  • Long history in anti-infective drug discovery, culminating with the invention of the block buster macrolide antibiotic azithromycin (Zithromax™, Sumamed™)
  • In house strain collection
    • >2000 bacterial and 800 fungal, fully characterized strains
    • Different resistance mechanisms against various antibiotic classes
    • Access to clinically relevant pathogens

In vitro compound profiling

Over 20 years of experience in antimicrobial compound profiling, testing against a vast number of relevant pathogens bearing different resistance patterns in class 2 pathogen certified labs, ensures skilled and comprehensive in vitro compound profiling, in assays like:
  • Antimicrobial susceptibility testing (CLSI/EUCAST guidelines compliant)
    • Microdilution, agar dilution, disk diffusion
    • MIC, MIC50, MIC90 and MBC determination
  • Drug combinations testing for synergy effects
    • FIC index determination
  • Time-kill studies
  • Resistance development propensity studies

Fidelta is experienced in developing custom assays as well as tailor-made assays for non-conventional compounds and/or with clinical isolates provided by clients.

Mechanism of action determination (MoA)

Based on experience with different classes of antimicrobials with diverse or unknown MoA and reverse pharmacology in general, Fidelta is confident to tackle any MoA demand with assays such as:
  • Macromolecular synthesis inhibition
    • Differentiating inhibitors of DNA, RNA, protein and cell wall synthesis
  • Inhibition of transcription and translation
  • Thymidine rescue

References

  • Hasenoehrl et al. 2006, Antimicrob Agents Chemother, 50, 3011
  • Alihodzic et al. 2006, J Antibiot, 59, 753
  • Kapic et al. 2010, Bioorg Med Chem, 18, 6569
  • Pesic et al. 2012, J Med Chem, 55, 3216
© 2015 All Rights Reserved - Fidelta Ltd.